Hybio Pharmaceutical's falling revenue and pre-tax losses po...

Hybio Pharmaceutical's falling revenue and pre-tax losses pose concerns over its debt level, implying potential threat to the company while its shares seem unaffected. It's deemed risky due to these factors.